Skip to main content
Top
Published in:

Open Access 21-09-2024 | Sickle Cell Anemia | Review

Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future

Authors: Susan Creary, Melissa G. Chung, Anthony D. Villella, Warren D. Lo

Published in: Current Neurology and Neuroscience Reports | Issue 11/2024

Login to get access

Abstract

Purpose of Review

Sickle cell anemia (SCA) is an autosomal recessive inherited hemoglobinopathy that results in a high risk of stroke. SCA primarily affects an underserved minority population of children who are frequently not receiving effective, multi-disciplinary, preventative care. This article reviews primary and secondary stroke prevention and treatment for children with SCA for the general adult and pediatric neurologist, who may play an important role in providing critical neurologic evaluation and care to these children.

Recent Findings

Primary stroke prevention is efficacious at reducing ischemic stroke risk, but it is not consistently implemented into clinical practice in the United States, resulting in these children remaining at high risk. Acute symptomatic stroke management requires neurology involvement and emergent transfusion to limit ischemia. Furthermore, while chronic transfusion therapy is a proven secondary preventative modality for those with prior symptomatic or silent cerebral infarcts, it carries significant burden. Newer therapies (e.g., stem cell therapies and voxelotor) deserve further study as they may hold promise in reducing stroke risk and treatment burden.

Summary

Effective primary and secondary stroke prevention and treatment remain a challenge. Informing and engaging neurology providers to recognize and provide critical neurologic evaluation and treatment has potential to close care gaps.
Literature
1.
go back to reference Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, DeBaun MR, et al. Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51–96.CrossRefPubMed Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, DeBaun MR, et al. Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51–96.CrossRefPubMed
2.
go back to reference Bhattacharya P, Sarmah D, Dave KR, Goswami A, Watanabe M, Wang X, et al. Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries. J Neurol Sci. 2021;427: 117510.CrossRefPubMed Bhattacharya P, Sarmah D, Dave KR, Goswami A, Watanabe M, Wang X, et al. Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries. J Neurol Sci. 2021;427: 117510.CrossRefPubMed
4.
go back to reference Mack AK, Thompson AA. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease. J Pediatr Health Care. 2017;31(2):145–54.CrossRefPubMed Mack AK, Thompson AA. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease. J Pediatr Health Care. 2017;31(2):145–54.CrossRefPubMed
5.
go back to reference Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157(1):14–25.CrossRefPubMed Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157(1):14–25.CrossRefPubMed
6.
go back to reference Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.CrossRefPubMed Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.CrossRefPubMed
8.
go back to reference Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407–12.CrossRefPubMed Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407–12.CrossRefPubMed
9.
go back to reference Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children: ethnic and gender disparities. Neurology. 2003;61(2):189–94.CrossRefPubMed Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children: ethnic and gender disparities. Neurology. 2003;61(2):189–94.CrossRefPubMed
10.
go back to reference Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35(3):242–8.CrossRefPubMed Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35(3):242–8.CrossRefPubMed
11.
go back to reference Debaun MR, Derdeyn CP, McKinstry RC 3rd. Etiology of strokes in children with sickle cell anemia. Ment Retard Dev Disabil Res Rev. 2006;12(3):192–9.CrossRefPubMed Debaun MR, Derdeyn CP, McKinstry RC 3rd. Etiology of strokes in children with sickle cell anemia. Ment Retard Dev Disabil Res Rev. 2006;12(3):192–9.CrossRefPubMed
12.
go back to reference Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.CrossRefPubMed Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.CrossRefPubMed
13.
go back to reference Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605–10.CrossRefPubMed Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605–10.CrossRefPubMed
14.
go back to reference Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial I. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–78.CrossRefPubMed Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial I. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–78.CrossRefPubMed
16.
go back to reference Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–70.CrossRefPubMed Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–70.CrossRefPubMed
17.
go back to reference DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699–710.CrossRefPubMedPubMedCentral DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699–710.CrossRefPubMedPubMedCentral
18.
go back to reference Kwiatkowski JL, Voeks JH, Kanter J, Fullerton HJ, Debenham E, Brown L, et al. Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019;94(12):1335–43.CrossRefPubMed Kwiatkowski JL, Voeks JH, Kanter J, Fullerton HJ, Debenham E, Brown L, et al. Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019;94(12):1335–43.CrossRefPubMed
19.
go back to reference Kwiatkowski JL, Zimmerman RA, Pollock AN, Seto W, Smith-Whitley K, Shults J, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146(3):300–5.CrossRefPubMedPubMedCentral Kwiatkowski JL, Zimmerman RA, Pollock AN, Seto W, Smith-Whitley K, Shults J, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146(3):300–5.CrossRefPubMedPubMedCentral
20.
go back to reference Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8):1109–11.CrossRefPubMed Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8):1109–11.CrossRefPubMed
21.
go back to reference Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99(8):3014–8.CrossRefPubMed Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99(8):3014–8.CrossRefPubMed
22.
go back to reference Rallo MS, Akel O, Kalakoti P, Sun H. Characteristics and outcomes of stroke hospitalizations in patients with sickle cell disease and moyamoya syndrome. J Stroke Cerebrovasc Dis. 2022;31(10): 106705.CrossRefPubMed Rallo MS, Akel O, Kalakoti P, Sun H. Characteristics and outcomes of stroke hospitalizations in patients with sickle cell disease and moyamoya syndrome. J Stroke Cerebrovasc Dis. 2022;31(10): 106705.CrossRefPubMed
23.
go back to reference Newman S, McMahon JT, Boulter JH, Malcolm JG, RevueltaBarbero JM, Chern JJ, et al. Revascularization Is Associated With a Reduced Stroke Risk in Patients With Sickle Cell-Associated Moyamoya Syndrome. Neurosurgery. 2022;90(4):441–6.CrossRefPubMed Newman S, McMahon JT, Boulter JH, Malcolm JG, RevueltaBarbero JM, Chern JJ, et al. Revascularization Is Associated With a Reduced Stroke Risk in Patients With Sickle Cell-Associated Moyamoya Syndrome. Neurosurgery. 2022;90(4):441–6.CrossRefPubMed
24.
go back to reference Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia A randomized trial. N Engl J Med. 1986;314(25):1593–9.CrossRefPubMed Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia A randomized trial. N Engl J Med. 1986;314(25):1593–9.CrossRefPubMed
26.
go back to reference Muschick K, Fuqua T, Stoker-Postier C, Anderson AR. Real-world data on voxelotor to treat patients with sickle cell disease. Eur J Haematol. 2022;109(2):154–61.CrossRefPubMed Muschick K, Fuqua T, Stoker-Postier C, Anderson AR. Real-world data on voxelotor to treat patients with sickle cell disease. Eur J Haematol. 2022;109(2):154–61.CrossRefPubMed
27.
go back to reference Reeves SL, Madden B, Freed GL, Dombkowski KJ. Transcranial doppler screening among children and adolescents with sickle cell anemia. JAMA Pediatr. 2016;170(6):550–6.CrossRefPubMedPubMedCentral Reeves SL, Madden B, Freed GL, Dombkowski KJ. Transcranial doppler screening among children and adolescents with sickle cell anemia. JAMA Pediatr. 2016;170(6):550–6.CrossRefPubMedPubMedCentral
28.
go back to reference Venketasubramanian N, Prohovnik I, Hurlet A, Mohr JP, Piomelli S. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. Stroke. 1994;25(11):2153–8.CrossRefPubMed Venketasubramanian N, Prohovnik I, Hurlet A, Mohr JP, Piomelli S. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. Stroke. 1994;25(11):2153–8.CrossRefPubMed
29.
go back to reference DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–88.CrossRefPubMedPubMedCentral DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–88.CrossRefPubMedPubMedCentral
30.
go back to reference Reeves SL, Fullerton HJ, Cohn LM, Dombkowski KJ, Boulton ML, Braun TM, et al. Missed opportunities for transcranial doppler screening among children with sickle cell disease. Clin Pediatr (Phila). 2016;55(12):1093–9.CrossRefPubMed Reeves SL, Fullerton HJ, Cohn LM, Dombkowski KJ, Boulton ML, Braun TM, et al. Missed opportunities for transcranial doppler screening among children with sickle cell disease. Clin Pediatr (Phila). 2016;55(12):1093–9.CrossRefPubMed
31.
go back to reference Reeves SL, Freed GL, Madden B, Wu M, Miller L, Cogan L, et al. Trends in quality of care among children with sickle cell anemia. Pediatr Blood Cancer. 2022;69(2): e29446.CrossRefPubMed Reeves SL, Freed GL, Madden B, Wu M, Miller L, Cogan L, et al. Trends in quality of care among children with sickle cell anemia. Pediatr Blood Cancer. 2022;69(2): e29446.CrossRefPubMed
32.
go back to reference Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51(5):647–51.CrossRefPubMed Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51(5):647–51.CrossRefPubMed
33.
go back to reference Reeves SL, Ng S, Dombkowski KJ, Raphael JL, Chua KP. TCD screening and spending among children with sickle cell anemia. Am J Manag Care. 2023;29(3):e79–84.CrossRefPubMedPubMedCentral Reeves SL, Ng S, Dombkowski KJ, Raphael JL, Chua KP. TCD screening and spending among children with sickle cell anemia. Am J Manag Care. 2023;29(3):e79–84.CrossRefPubMedPubMedCentral
34.
go back to reference Cabana MD, Kanter J, Marsh AM, Treadwell MJ, Rowland M, Stemmler P, et al. Barriers to pediatric sickle cell disease guideline recommendations. Glob Pediatr Health. 2019;6:2333794X19847026.CrossRefPubMedPubMedCentral Cabana MD, Kanter J, Marsh AM, Treadwell MJ, Rowland M, Stemmler P, et al. Barriers to pediatric sickle cell disease guideline recommendations. Glob Pediatr Health. 2019;6:2333794X19847026.CrossRefPubMedPubMedCentral
35.
go back to reference Davidow KA, Miller R, Phillips SM, Schlenz AM, Mueller M, Hulbert ML, et al. Displace study shows poor quality of transcranial doppler ultrasound for stroke risk screening in sickle cell anemia. Blood Adv. 2024;8(13):3444–52.CrossRefPubMedPubMedCentral Davidow KA, Miller R, Phillips SM, Schlenz AM, Mueller M, Hulbert ML, et al. Displace study shows poor quality of transcranial doppler ultrasound for stroke risk screening in sickle cell anemia. Blood Adv. 2024;8(13):3444–52.CrossRefPubMedPubMedCentral
36.
go back to reference Bollinger LM, Nire KG, Rhodes MM, Chisolm DJ, O’Brien SH. Caregivers’ perspectives on barriers to transcranial Doppler screening in children with sickle-cell disease. Pediatr Blood Cancer. 2011;56(1):99–102.CrossRefPubMed Bollinger LM, Nire KG, Rhodes MM, Chisolm DJ, O’Brien SH. Caregivers’ perspectives on barriers to transcranial Doppler screening in children with sickle-cell disease. Pediatr Blood Cancer. 2011;56(1):99–102.CrossRefPubMed
38.
go back to reference Hawkins LM, Sinha CB, Ross D, Yee MEM, Quarmyne MO, Krishnamurti L, et al. Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study. BMC Pediatr. 2020;20(1):172.CrossRefPubMedPubMedCentral Hawkins LM, Sinha CB, Ross D, Yee MEM, Quarmyne MO, Krishnamurti L, et al. Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study. BMC Pediatr. 2020;20(1):172.CrossRefPubMedPubMedCentral
39.
go back to reference Verlhac S, Gabor F, Paillard C, Chateil JF, Jubert C, Petras M, et al. Improved stenosis outcome in stroke-free sickle cell anemia children after transplantation compared to chronic transfusion. Br J Haematol. 2021;193(1):188–93.CrossRefPubMed Verlhac S, Gabor F, Paillard C, Chateil JF, Jubert C, Petras M, et al. Improved stenosis outcome in stroke-free sickle cell anemia children after transplantation compared to chronic transfusion. Br J Haematol. 2021;193(1):188–93.CrossRefPubMed
40.
go back to reference Hulbert ML, Fields ME, Guilliams KP, Bijlani P, Shenoy S, Fellah S, et al. Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease. Blood. 2023;141(4):335–44.CrossRefPubMed Hulbert ML, Fields ME, Guilliams KP, Bijlani P, Shenoy S, Fellah S, et al. Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease. Blood. 2023;141(4):335–44.CrossRefPubMed
41.
go back to reference Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11–21.CrossRefPubMed Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11–21.CrossRefPubMed
42.
go back to reference Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):708–18.CrossRefPubMedPubMedCentral Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):708–18.CrossRefPubMedPubMedCentral
43.
go back to reference Sporns PB, Psychogios M. Thrombectomy in Childhood Stroke: Important Considerations in Borderline Indications. Stroke. 2020;51(10):2890–1.CrossRefPubMed Sporns PB, Psychogios M. Thrombectomy in Childhood Stroke: Important Considerations in Borderline Indications. Stroke. 2020;51(10):2890–1.CrossRefPubMed
44.
go back to reference Kaviany S, Barnawi Z, LaBelle J. Curative Therapies for Sickle Cell Disease. Pediatr Ann. 2024;53(2):e56–61.CrossRefPubMed Kaviany S, Barnawi Z, LaBelle J. Curative Therapies for Sickle Cell Disease. Pediatr Ann. 2024;53(2):e56–61.CrossRefPubMed
45.
go back to reference Carpenter JL, Nickel RS, Webb J, Khademian Z, Speller-Brown B, Majumdar S, et al. Low rates of cerebral infarction after hematopoietic stem cell transplantation in patients with sickle cell disease at high risk for stroke. Transplant Cell Ther. 2021;27(12):1018 e1-e9.CrossRefPubMed Carpenter JL, Nickel RS, Webb J, Khademian Z, Speller-Brown B, Majumdar S, et al. Low rates of cerebral infarction after hematopoietic stem cell transplantation in patients with sickle cell disease at high risk for stroke. Transplant Cell Ther. 2021;27(12):1018 e1-e9.CrossRefPubMed
46.
go back to reference Kelleher SC, Kirkham FJ, Hood AM. Executive function and processing speed in children living with sickle cell anemia. Children (Basel). 2023;10(10):1585.PubMed Kelleher SC, Kirkham FJ, Hood AM. Executive function and processing speed in children living with sickle cell anemia. Children (Basel). 2023;10(10):1585.PubMed
47.
go back to reference Ford AL, Ragan DK, Fellah S, Binkley MM, Fields ME, Guilliams KP, et al. Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow. Blood. 2018;132(16):1714–23.CrossRefPubMedPubMedCentral Ford AL, Ragan DK, Fellah S, Binkley MM, Fields ME, Guilliams KP, et al. Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow. Blood. 2018;132(16):1714–23.CrossRefPubMedPubMedCentral
48.
go back to reference Jordan LC, Juttukonda MR, Kassim AA, DeBaun MR, Davis LT, Pruthi S, et al. Haploidentical bone marrow transplantation improves cerebral hemodynamics in adults with sickle cell disease. Am J Hematol. 2019;94(6):E155–8.CrossRefPubMedPubMedCentral Jordan LC, Juttukonda MR, Kassim AA, DeBaun MR, Davis LT, Pruthi S, et al. Haploidentical bone marrow transplantation improves cerebral hemodynamics in adults with sickle cell disease. Am J Hematol. 2019;94(6):E155–8.CrossRefPubMedPubMedCentral
49.
go back to reference Aumann MA, Richerson W, Song AK, Davis LT, Pruthi S, Davis S, et al. Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease. Blood Adv. 2024;8(3):608–19.CrossRefPubMed Aumann MA, Richerson W, Song AK, Davis LT, Pruthi S, Davis S, et al. Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease. Blood Adv. 2024;8(3):608–19.CrossRefPubMed
50.
go back to reference Amlie-Lefond C, Flanagan J, Kanter J, Dobyns WB. The genetic landscape of cerebral steno-occlusive arteriopathy and stroke in sickle cell anemia. J Stroke Cerebrovasc Dis. 2018;27(11):2897–904.CrossRefPubMed Amlie-Lefond C, Flanagan J, Kanter J, Dobyns WB. The genetic landscape of cerebral steno-occlusive arteriopathy and stroke in sickle cell anemia. J Stroke Cerebrovasc Dis. 2018;27(11):2897–904.CrossRefPubMed
51.
go back to reference Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med. 2013;64:451–66.CrossRefPubMed Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med. 2013;64:451–66.CrossRefPubMed
52.
go back to reference Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS 3rd, Hilliard L, Bemrich-Stolz CJ, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16(1):64–73.CrossRefPubMed Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS 3rd, Hilliard L, Bemrich-Stolz CJ, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16(1):64–73.CrossRefPubMed
53.
go back to reference Hall EM, Leonard J, Smith JL, Guilliams KP, Binkley M, Fallon RJ, et al. Reduction in overt and silent stroke recurrence rate following cerebral revascularization surgery in children with sickle cell disease and severe cerebral vasculopathy. Pediatr Blood Cancer. 2016;63(8):1431–7.CrossRefPubMedPubMedCentral Hall EM, Leonard J, Smith JL, Guilliams KP, Binkley M, Fallon RJ, et al. Reduction in overt and silent stroke recurrence rate following cerebral revascularization surgery in children with sickle cell disease and severe cerebral vasculopathy. Pediatr Blood Cancer. 2016;63(8):1431–7.CrossRefPubMedPubMedCentral
54.
go back to reference Aldana PR, Hanel RA, Piatt J, Han SH, Bansal MM, Schultz C, et al. Cerebral revascularization surgery reduces cerebrovascular events in children with sickle cell disease and moyamoya syndrome: Results of the stroke in sickle cell revascularization surgery retrospective study. Pediatr Blood Cancer. 2023;70(7): e30336.CrossRefPubMed Aldana PR, Hanel RA, Piatt J, Han SH, Bansal MM, Schultz C, et al. Cerebral revascularization surgery reduces cerebrovascular events in children with sickle cell disease and moyamoya syndrome: Results of the stroke in sickle cell revascularization surgery retrospective study. Pediatr Blood Cancer. 2023;70(7): e30336.CrossRefPubMed
55.
go back to reference Bernaudin F, Verlhac S, Peffault de Latour R, Dalle JH, Brousse V, Petras E, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial doppler velocities in children with sickle cell anemia. JAMA. 2019;321(3):266–76.CrossRefPubMedPubMedCentral Bernaudin F, Verlhac S, Peffault de Latour R, Dalle JH, Brousse V, Petras E, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial doppler velocities in children with sickle cell anemia. JAMA. 2019;321(3):266–76.CrossRefPubMedPubMedCentral
56.
go back to reference Al-Jefri A, Siddiqui K, Al-Oraibi A, Al-Seraihy A, Al Ahmari A, Ghemlas I, et al. Hematopoietic stem cell transplantation stabilizes cerebral vasculopathy in high-risk pediatric sickle cell disease patients: evidence from a referral transplant center. J Hematol. 2022;11(1):8–14.CrossRefPubMedPubMedCentral Al-Jefri A, Siddiqui K, Al-Oraibi A, Al-Seraihy A, Al Ahmari A, Ghemlas I, et al. Hematopoietic stem cell transplantation stabilizes cerebral vasculopathy in high-risk pediatric sickle cell disease patients: evidence from a referral transplant center. J Hematol. 2022;11(1):8–14.CrossRefPubMedPubMedCentral
57.
go back to reference Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252–60.CrossRefPubMed Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252–60.CrossRefPubMed
58.
go back to reference Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617–28.CrossRefPubMed Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617–28.CrossRefPubMed
59.
go back to reference Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772–9.CrossRefPubMedPubMedCentral Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772–9.CrossRefPubMedPubMedCentral
60.
go back to reference Stollon NB, Paine CW, Lucas MS, Brumley LD, Poole ES, Peyton T, et al. Transitioning adolescents and young adults with sickle cell disease from pediatric to adult health care: provider perspectives. J Pediatr Hematol Oncol. 2015;37(8):577–83.CrossRefPubMedPubMedCentral Stollon NB, Paine CW, Lucas MS, Brumley LD, Poole ES, Peyton T, et al. Transitioning adolescents and young adults with sickle cell disease from pediatric to adult health care: provider perspectives. J Pediatr Hematol Oncol. 2015;37(8):577–83.CrossRefPubMedPubMedCentral
61.
go back to reference Kassim AA, Pruthi S, Day M, Rodeghier M, Gindville MC, Brodsky MA, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016;127(16):2038–40.CrossRefPubMed Kassim AA, Pruthi S, Day M, Rodeghier M, Gindville MC, Brodsky MA, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016;127(16):2038–40.CrossRefPubMed
62.
go back to reference Jordan LC, Kassim AA, Donahue MJ, Juttukonda MR, Pruthi S, Davis LT, et al. Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia. Neurology. 2018;91(8):e781–4.CrossRefPubMedPubMedCentral Jordan LC, Kassim AA, Donahue MJ, Juttukonda MR, Pruthi S, Davis LT, et al. Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia. Neurology. 2018;91(8):e781–4.CrossRefPubMedPubMedCentral
63.
go back to reference Jones RS, Ford AL, Donahue MJ, Fellah S, Davis LT, Pruthi S, et al. Distribution of silent cerebral infarcts in adults with sickle cell disease. Neurology. 2024;102(10): e209247.CrossRefPubMed Jones RS, Ford AL, Donahue MJ, Fellah S, Davis LT, Pruthi S, et al. Distribution of silent cerebral infarcts in adults with sickle cell disease. Neurology. 2024;102(10): e209247.CrossRefPubMed
64.
go back to reference Prussien KV, Compas BE, Siciliano RE, Ciriegio AE, Lee CA, Kassim AA, et al. Cerebral hemodynamics and executive function in sickle cell anemia. Stroke. 2021;52(5):1830–4.CrossRefPubMedPubMedCentral Prussien KV, Compas BE, Siciliano RE, Ciriegio AE, Lee CA, Kassim AA, et al. Cerebral hemodynamics and executive function in sickle cell anemia. Stroke. 2021;52(5):1830–4.CrossRefPubMedPubMedCentral
65.
go back to reference Light J, Boucher M, Baskin-Miller J, Winstead M. Managing the cerebrovascular complications of sickle cell disease: current perspectives. J Blood Med. 2023;14:279–93.CrossRefPubMedPubMedCentral Light J, Boucher M, Baskin-Miller J, Winstead M. Managing the cerebrovascular complications of sickle cell disease: current perspectives. J Blood Med. 2023;14:279–93.CrossRefPubMedPubMedCentral
66.
go back to reference Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–39.CrossRefPubMed Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–39.CrossRefPubMed
67.
go back to reference Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, et al. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014;164(5):1175-80.e1.CrossRefPubMedPubMedCentral Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, et al. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014;164(5):1175-80.e1.CrossRefPubMedPubMedCentral
Metadata
Title
Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future
Authors
Susan Creary
Melissa G. Chung
Anthony D. Villella
Warren D. Lo
Publication date
21-09-2024
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 11/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-024-01372-9

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more